Noocholine Rompharm, 250 mg/ml 4 ml 3 pcs

Noocholine Rompharm is a nootropic drug, a cholinomimetic of central action with predominant effect on the CNS. The drug contains 40.5% of metabolically protected choline. Choline alphocerate is broken down into choline and glycerophosphate in the body under the influence of brain enzymes. Choline is involved in the synthesis of acetylcholine, transmitting nerve impulses and improving brain function, and glycerophosphate is a precursor of phosphatidylcholine of neuronal membranes.

Choline alphoscerate improves cerebral blood flow, enhances metabolic processes in the brain, activates structures of the reticular formation of the brain and restores consciousness in traumatic brain injury.

The results of clinical studies have shown that choline alphoscerate stimulates the dose-dependent release of acetylcholine under physiological conditions of neurotransmission.

Pharmacokinetics

Distribution

It penetrates readily into various tissues and organs, including the brain.

Elimination

Extracted mainly by the lungs as carbon dioxide (85%), but also excreted by the kidneys and through the intestines (15%).

Indications

Active ingredient

Composition

Active ingredient:

choline alphoscerate 250 mg;

Helpful Substance:

water

How to take, the dosage

In acute conditions, administer by m/m or intravenous (slowly), 1 g per day for 15-20 days; then switch to oral administration at 0.8 g in the morning and 0.4 g during the day for 6 months.

Contraindications

Hemorrhagic stroke (acute stage); hypersensitivity to components of the drug.

Side effects

Digestive system disorders: constipation, diarrhea, dry oral mucosa, pharyngitis.

Nervous system disorders: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, cerebral ischemia, dizziness.

Skin side: rash, urticaria.

Others: pain at the site of injection, increased frequency of urination.

Overdose

Symptoms: in case of overdose, nausea is noted, which subsides after reduction of the dose or discontinuation of treatment.

Treatment: symptomatic therapy.

Pregnancy use

The use of the drug during pregnancy and lactation is contraindicated.

Breast-feeding should be stopped during treatment.

The drug has no teratogenic and mutagenic effect.

Similarities